NEW YORK, Jan. 20 (GenomeWeb News) - Mergen and Oxford Gene Technology agreed on Jan. 13 to settle the patent-infringement litigation between them, according to Mergen spokesperson Jamie Love.

Under the terms of the deal, Sunnyvale, Calif.-based Mergen has purchased a license from Oxford, UK-based OGT allowing the company to manufacture and sell microarrays for investigating gene expression. Mergen has also dropped a countersuit as part of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.